Grey Fox Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Grey Fox Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-161	Closed	-$8.72K	–	187
2025 Q3	$8.72K	Buy	+161	New	+$9.21K	﹤0.01%	421
2023 Q2	–	Sell	-202	Closed	-$19.6K	–	152
2023 Q1	$19.6K	Sell	202 -100	-33%	-$10.4K	0.01%	258
2022 Q4	$31.3K	Buy	+302	New	+$28.4K	0.02%	198

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Grey Fox Wealth Advisors's BMRN Position: Q4 2025 in Review

Grey Fox Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 161 shares — an estimated $8.72K sold.

Grey Fox Wealth Advisors first reported a position in BMRN in Q4 2022 and held it in 3 quarters. The position peaked at $31.3K in Q4 2022. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Grey Fox Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Grey Fox Wealth Advisors sold 161 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $8.72K.
Grey Fox Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 3 quarters.
Grey Fox Wealth Advisors's BioMarin Pharmaceuticals position peaked at $31.3K in Q4 2022.
538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Grey Fox Wealth Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.